Condition: Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF) · Sponsor: Novartis Pharmaceuticals
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Summit Medical Group Oncology | Berkeley Heights, New Jersey, United States | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| Novartis Investigative Site | Buenos Aires, Buenos Aires F.D., Argentina | Recruiting |
| Novartis Investigative Site | Capital Federal, Argentina | Recruiting |
| Novartis Investigative Site | Clayton, Victoria, Australia | Recruiting |
| Novartis Investigative Site | Hefei, Anhui, China | Recruiting |
| Novartis Investigative Site | Guangzhou, Guangdong, China | Recruiting |
| Novartis Investigative Site | Nantong, Jiangsu, China | Recruiting |
| Novartis Investigative Site | Yantai, Shandong, China | Recruiting |
| Novartis Investigative Site | Wenzhou, Zhejiang, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Chongqing, China | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07357727